Cardio Diagnostics Holdings, Inc. (Cardio) has entered into an at-the-market offering agreement with Craig-Hallum Capital Group LLC, enabling the sale of up to $17 million in common stock. This arrangement allows Cardio to sell shares through Craig-Hallum, acting as an agent or principal, directly on the Nasdaq where Cardio's common stock and public warrants are listed under the symbols 'CDIO' and 'CDIOW,' respectively. The sales agreement is in accordance with the terms of the prospectus supplement and the accompanying prospectus. The offering may be made through various methods, including ordinary broker transactions and privately negotiated deals. The compensation to Craig-Hallum is set at 2.5% of the gross proceeds from the sale of shares. The net proceeds...Show More

Cardio Diagnostics Holdings, Inc. (Cardio) has entered into an at-the-market offering agreement with Craig-Hallum Capital Group LLC, enabling the sale of up to $17 million in common stock. This arrangement allows Cardio to sell shares through Craig-Hallum, acting as an agent or principal, directly on the Nasdaq where Cardio's common stock and public warrants are listed under the symbols 'CDIO' and 'CDIOW,' respectively. The sales agreement is in accordance with the terms of the prospectus supplement and the accompanying prospectus. The offering may be made through various methods, including ordinary broker transactions and privately negotiated deals. The compensation to Craig-Hallum is set at 2.5% of the gross proceeds from the sale of shares. The net proceeds from the offering will depend on the actual number of shares sold and the market price at which they are sold. Cardio, an emerging growth company, focuses on developing epigenetics-based clinical tests for cardiovascular diseases. The company's tests, Epi+Gen CHD™ and PrecisionCHD™, are designed to improve prevention, early detection, and treatment of cardiovascular disease. The announcement of the prospectus supplement was made on February 1, 2024.